Xiangtian Kong
Papers
1
Total Citations
2
H-Index
1
About
Xiangtian Kong is a pioneering surgical oncologist whose research focuses on the intersection of immunotherapy, minimally invasive surgery, and head and neck oncology. Dr. Kong’s most cited work, a 2024 study on neoadjuvant chemoimmunotherapy (NACI) combined with transoral robotic surgery (TORS) for locally advanced oropharyngeal squamous cell carcinoma, has already garnered 2 citations, marking a significant early impact in the field. This landmark paper demonstrates that NACI followed by TORS offers a safe, effective, and minimally invasive treatment paradigm, potentially transforming standard care for patients with this challenging disease. By integrating cutting-edge immunotherapeutic strategies with robotic precision, Dr. Kong’s contributions address critical gaps in organ preservation and functional outcomes. Their work is particularly notable for advancing personalized, less morbid approaches to head and neck cancer, bridging the gap between systemic therapy and surgical innovation. With a growing citation footprint and a focus on translating bench-to-bedside discoveries, Dr. Kong stands as a rising leader in head and neck surgical oncology, inspiring future research into combined modality treatments that prioritize both oncologic efficacy and patient quality of life.
Research Focus
Key Achievements
Top Papers
- 1